APA (7th ed.) Citation

B, Y., M, B., S, S., MP, N., EN, H., A, C., . . . LR, K. (2026). Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study. Infectious diseases and therapy, 15(4), 1047. https://doi.org/10.1007/s40121-026-01311-w

Chicago Style (17th ed.) Citation

B, Yarnoff, et al. "Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study." Infectious Diseases and Therapy 15, no. 4 (2026): 1047. https://doi.org/10.1007/s40121-026-01311-w.

MLA (9th ed.) Citation

B, Yarnoff, et al. "Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study." Infectious Diseases and Therapy, vol. 15, no. 4, 2026, p. 1047, https://doi.org/10.1007/s40121-026-01311-w.